PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Clinical trial NCT06078670 · UNKNOWN

Trial details

NCT number: NCT06078670
Sponsor: Fujian Cancer Hospital
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2023-10-10
Primary completion: 2026-06-01
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.